Sage Therapeutics announces topline results from the Phase 2 DIMENSION study of dalzanemdor in Huntington’s disease
- The Phase 2 DIMENSION study evaluated dalzanemdor for cognitive impairment in Huntington’s Disease.
- Dalzanemdor did not show a statistically significant difference from placebo on the primary endpoint, SDMT, at Day 84.
- Secondary endpoints also showed no significant or clinically meaningful differences.
- Sage Therapeutics will not pursue further development of dalzanemdor and will close the ongoing PURVIEW safety study.
Read more
